A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT01248949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT01248949
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Interventions
- Bevacizumab Drug
- Carboplatin Drug
- MEDI3617 Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2010
- Primary completion
- Jun 30, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Mar 28, 2017
2010 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | — | — |
| Research Site | Stanford | California | — | — |
| Research Site | Lafayette | Indiana | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Buffalo | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01248949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2017 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01248949 live on ClinicalTrials.gov.